Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment

Part of paid clinical trials in Berkeley, California.

Sponsor
University of California, Berkeley
Study ID
NCT07606625
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Varenicline 0.03Mg/Spray Nasal Soln — DRUG
    After meeting eligibility criteria and signing informed consent, participants will be dispensed a 3-month supply of varenicline 0.03mg/spray nasal solution. Participants will take the nasal spray home and spray once in each nostril twice daily for 3 months

Study Details

The purpose of this study is to examine the impact of nasal spray treatment on Meibomian gland function and ocular surface health in symptomatic dry eye patients with mild to moderate Meibomian gland dysfunction (MGD).

Key Dates

Start date
Mar 6, 2026
Status verified
May 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
65 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nasal Spray Treatment Group
    Participants to be dispensed varenicline nasal spray 0.03mg solution and self-administer one spray in each nostril twice daily, approximately 12 hours apart, for 3 months.

Primary Outcome Measure

Change in tear lipid layer thickness [ Time Frame: Measured at baseline, 1-month, and 3 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
U.C. Berkeley Clinical Research CenterBerkeleyCalifornia94720
Meng C. Lin, OD, PhD
[email protected]
510-643-9252
Laimeng Lee, OD, MS
[email protected]
510-643-9252

Find similar trials in Berkeley, CA

By research site
U.C. Berkeley Clinical Research Center· Berkeley, CA

Related Studies